MedTrace Logo

Pharmacokinetics of Aqueous Dexamethasone

NCT04667507 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2024-10-21

No results posted yet for this study

Summary

The study is being done to measure the absorption of the DEXTENZA implant and inflammation concentration levels in the eye.

Conditions

  • Pharmacokinetics
  • Aqueous Dexamethasone
  • Inflammatory Cytokine Response

Interventions

DRUG

Dexamethasone Ophthalmic implant

Dexamethasone ophthalmic insert 0.4 mg for intracanalicular use

Sponsors & Collaborators

  • Frank A. Bucci, Jr., M.D.

    lead OTHER

Principal Investigators

  • Frank A Bucci, Jr., MD · Bucci Laser Vision Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2021-10-31
Completion
2022-06-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04667507 on ClinicalTrials.gov